Holen Sie sich die Stockscreener-App
16.80
0.60%
0.10
Handel nachbörslich:
16.81
0.010
+0.06%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$16.70
Offen:
$16.7
24-Stunden-Volumen:
10.86M
Relative Volume:
1.03
Marktkapitalisierung:
$19.56B
Einnahmen:
$14.57B
Nettoeinkommen (Verlust:
$-296.50M
KGV:
-64.86
EPS:
-0.259
Netto-Cashflow:
$1.64B
1W Leistung:
+3.51%
1M Leistung:
+5.79%
6M Leistung:
+35.48%
1J Leistung:
+80.26%
1-Tages-Spanne:
$16.61
$16.98
1-Wochen-Bereich:
$15.79
$16.98
52-Wochen-Spanne:
$8.625
$17.53
Viatris Inc Stock (VTRS) Company Profile
Firmenname
Viatris Inc
Sektor
Telefon
(724) 514-1465
Adresse
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
16.80 | 18.49B | 14.57B | -296.50M | 1.64B | -0.259 |
TAK
Takeda Pharmaceutical Co Adr
|
16.89 | 50.65B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.72 | 41.09B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.29 | 39.45B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
75.42 | 30.13B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
547.25 | 23.00B | 3.17B | 1.29B | 1.01B | 27.09 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-09 | Hochstufung | UBS | Neutral → Buy |
| 2026-01-16 | Hochstufung | Argus | Hold → Buy |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-15 | Eingeleitet | Truist | Buy |
| 2025-06-06 | Eingeleitet | Goldman | Neutral |
| 2024-07-19 | Fortgesetzt | Jefferies | Buy |
| 2023-10-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-06-23 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2023-04-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-02-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-10 | Hochstufung | UBS | Sell → Neutral |
| 2022-11-08 | Hochstufung | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | Fortgesetzt | Jefferies | Hold |
| 2022-06-14 | Eingeleitet | UBS | Sell |
| 2022-05-10 | Herabstufung | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | Eingeleitet | Citigroup | Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2021-03-08 | Herabstufung | Goldman | Buy → Neutral |
| 2021-03-02 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-02-26 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | Eingeleitet | Argus | Hold |
| 2020-12-14 | Eingeleitet | Bernstein | Mkt Perform |
Alle ansehen
Viatris Inc Aktie (VTRS) Neueste Nachrichten
Form 4 Viatris Inc For: 1 July By Investing.com - Investing.com Canada
Viatris (VTRS) director David S. Simmons granted 2,362 deferred stock units as fees - Stock Titan
Viatris (VTRS) director takes 2,756 deferred stock units instead of cash fees - Stock Titan
Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch
ViatrisEnters Amended And Restated Term Loan Credit Agreement On July 1, 2026SEC Filing - TradingView
Viatris Secures ¥40 Billion Three-Year Term Loan With Mizuho to Refinance 2021 Facility - TradingView
Viatris (NASDAQ: VTRS) signs ¥40B three-year unsecured term loan deal - Stock Titan
Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026 - BioSpace
The Bull Case For Viatris (VTRS) Could Change Following Positive Japan Phase 3 Data For VR-205 - simplywall.st
VTRSViatris Inc Latest SEC Filings - Finviz
Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch
Securities Fraud Class Action Filed Against Viatris Inc. (VTRS) Levi & Korsinsky Reminds Investors of June 3, 2025 - The National Law Review
Viatris reports positive phase 3 results for IgAN drug in Japan By Investing.com - Investing.com India
(VTRS) Risk Channels and Responsive Allocation - Stock Traders Daily
How is Viatris’ stock performance compared to other healthcare stocks? - MSN
Viatris reports positive Japanese phase 3 results for Nefecon in IgAN - MSN
Viatris reports positive phase 3 results for IgAN drug in Japan - Investing.com South Africa
Viatris' VR-205 Meets Primary, Key Secondary Endpoints in Japanese Phase 3 Trial in Kidney Disease - marketscreener.com
Viatris (VTRS) Reports Positive Phase 3 Trial Results for VR-205 - GuruFocus
Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy - PR Newswire
Join Class Action to Recover Losses from Viatris Inc. (VTRS)Contact Levi & Korsinsky Before June 3, 2025 - The National Law Review
Enterprise value to EBITDA forward of Viatris Inc. – NASDAQ:VTRS - TradingView
Viatris interim CFO Paul Campbell sells $809,784 in stock By Investing.com - Investing.com South Africa
Viatris interim CFO Paul Campbell sells $809,784 in stock - Investing.com UK
Form 4 Viatris Inc For: 26 June By Investing.com - Investing.com South Africa
Enterprise value to revenue forward of Viatris Inc. – NASDAQ:VTRS - TradingView
Viatris Inc. stock rises Friday, outperforms market - MarketWatch
Planned sale: Viatris (VTRS) officer disposes 50,076 shares - Stock Titan
Viatris | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Viatris, Inc. Actuals & Estimates (FWB:VIA) - TradingView
Price to sales forward of Viatris Inc. – NASDAQ:VTRS - TradingView
Viatris, Inc. Actuals & Estimates (SWB:VIA) - TradingView
Viatris, Inc. Actuals & Estimates (BMV:VTRS) - TradingView
Viatris Inc (VTRS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Viatris, Inc. Actuals & Estimates (DUS:VIA) - TradingView
Form 144 Viatris Inc For: 25 June By Investing.com - Investing.com Nigeria
Viatris (VTRS) Rule 144 notice lists 49,715 vested shares and other entries - Stock Titan
VTRS Forecast — Price Target — Prediction for 2027 - TradingView
How Viatris’ €650 Million Eurobond Issue (VTRS) Has Changed Its Investment Story - simplywall.st
Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
Viatris Soared 54%: Time To Be More Careful (Rating Downgrade) (NASDAQ:VTRS) - Seeking Alpha
Are Investors Undervaluing Viatris (VTRS) Right Now? - Yahoo Finance
Viatris (VTRS) Q4 2025 Earnings Call Transcript - Fortune
Viatris Inc. (VTRS) Investor Outlook: Is The 15.89% Potential Upside Worth The Risk? - DirectorsTalk Interviews
Come As You Are: Emily Smith Builds Solidarity, Support for LGBTQ+ Colleagues Through VIVID - CSRwire
How Is Viatris’ Stock Performance Compared to Other Healthcare Stocks? - Barchart.com
Viatris Inc. stock falls Thursday, underperforms market - MarketWatch
Viatris Issues €650 Million Senior Notes to Refinance Debt - TipRanks
Finanzdaten der Viatris Inc-Aktie (VTRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.09%
0.52%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):